Amikacin Dosing and Monitoring Guidelines

Introduction to Amikacin Dosing

• The Infectious Diseases Society of America recommends administering 10-15 mg/kg/day IV for standard daily dosing, with a reduction to 10 mg/kg/day for patients over 59 years 1, 2, 3
• For intermittent dosing, 15-25 mg/kg per dose, three times weekly, is preferred when prolonged therapy is needed to reduce cumulative toxicity 1, 2

Dosing Considerations

• The American Thoracic Society suggests that a fixed 500 mg dose ignores patient weight entirely, risking underdosing and treatment failure 1, 2, 3, 4
• Every-other-day dosing is not supported by guidelines for IV amikacin in most clinical scenarios, and may lead to inadequate trough levels and reduced efficacy 1, 2

Therapeutic Drug Monitoring

• The European Respiratory Society recommends target trough levels of <5 mg/L to prevent toxicity, and peak levels of 25-45 μg/mL with daily dosing and 65-80 μg/mL with intermittent dosing 2, 3, 5, 6
• Monitoring peak levels within the first week, and trough levels weekly for 4 weeks, then every 2 weeks when stable, is essential for preventing toxicity 3, 5

Toxicity Monitoring

• The American College of Chest Physicians suggests monitoring renal function monthly, and reducing dose or increasing dosing interval in renal impairment to prevent nephrotoxicity 1, 2, 5, 6
• Baseline audiometry and intermittent monitoring during treatment are crucial for detecting ototoxicity, which is defined as a 20 dB loss at any one frequency or 10 dB loss at two adjacent frequencies 5, 6

Clinical Context

• For NTM pulmonary disease, nebulized amikacin 500 mg twice daily or IV amikacin with weight-based dosing (10-15 mg/kg/day or 15-25 mg/kg three times weekly) may be used for treatment-refractory MAC disease 4, 5, 1
• In other severe infections, once-daily dosing of 15 mg/kg IV may show high cure rates and reduced nephrotoxicity compared to divided dosing 4, 1